Skip to main content
Showing 1 - 5 out of 49
On Demand

JAMIA Journal Club Webinar - December 2024

Type
Webinar
Can GPT-3.5 generate and code discharge summaries? Read the abstract Presenter Matúš Falis is a Research Fellow in the Centre for Clinical Brain Sciences at the University of Edinburgh and an Associate Natural Language Processing Data Analyst at DataLoch. His current research focuses on identifying response and adverse reaction to [...]
On Demand

Smarter Cancer Solutions with GenAI

Type
Webinar
Please join our webinar for an engaging discussion on GenAI in oncology. The conversation will explore the transformative potential of generative AI, highlighting use cases such as precision medicine and clinical trial matching. Panelists will discuss the institutional clinical research landscape, focusing on the practical considerations of implementing AI solutions [...]
On Demand

AMIA 10x10 with Oregon Health & Science University

-
Type
AMIA 10x10
Credits
46.50
CME
Introduction to Biomedical and Health Informatics The Department of Medical Informatics & Clinical Epidemiology (DMICE) at Oregon Health & Science University will be offering another Biomedical Informatics Distance Learning Course as part of the AMIA 10x10 Program. The goal of this course is to provide a detailed overview of biomedical [...]
On Demand

Generative AI for Oncology Care and Research

Type
Webinar
Applying generative AI to oncology offers the potential for transformative advances in both patient care and cancer research. This webinar aims to delve into the nuance behind best-practice use cases and applications of generative AI within oncology. Experts will explore how these technologies can be integrated into clinical trials, clinical [...]
On Demand

JAMIA Journal Club Webinar - October 2024

Type
Webinar
Credits
1.00
CME
1.00
CNE
Multiple sclerosis (MS) is a debilitating chronic inflammatory disease affecting the central nervous system, with significant implications for millions worldwide, particularly young adults. Current treatments for MS, known as disease-modifying therapies (DMTs), are aimed at reducing relapse rates and delaying disease progression